4"-O-propenoyl-6-O-methyl-erythromycin A | 528851-75-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4"-O-propenoyl-6-O-methyl-erythromycin A
• 英文别名: 4"-O-propenoyl-6-O-methylerythromycin A；4"-O-propenoyl-6-O-methylerythromycin；4''-O-propenoyl-6-O-methylerythromycin A；[(2S,3S,4R,6R)-6-[[(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-7-methoxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-4-yl]oxy]-4-methoxy-2,4-dimethyloxan-3-yl] prop-2-enoate
• CAS: 528851-75-4
• 化学式: C₄₁H₇₁NO₁₄
• 分子量: 802.013
• InChiKey: BMMOFDJYJYNUNS-JDYRIQGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  56
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  189
• 氢给体数：
  3
• 氢受体数：
  15

反应信息

• 作为反应物：
  描述：

  4"-O-propenoyl-6-O-methyl-erythromycin A 、 6-(3-Aminopropyl)-1-(dimethylamino)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid hydrochloride 在 水 、 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 12.0h， 生成 4''-O-{3-[3-(3-carboxy-1,4-dihydro-1-dimethylamino-4-oxo-6-quinolinyl)propylamino]propionyl}-6-O-methylerythromycin A
  参考文献：
  名称：

  WO2006/50942

  摘要：

  公开号：
• 作为产物：
  描述：

  11-deoxy-11-(carboxyamino)-6-O-methylerythromycin A 11,12-(cyclic ester) 在 甲醇 、 碳酸氢钠 、 三乙胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 20.33h， 生成 4"-O-propenoyl-6-O-methyl-erythromycin A
  参考文献：
  名称：

  [EN] NOVEL 14 AND 15 MEMBERRED-RING COMPOUNDS
  [FR] NOUVEAUX COMPOSES A CYCLE RAMIFIE EN 14 ET 15

  摘要：

  本发明涉及在式（I）的4'位置被取代的14-或15-元大环内酯及其药用可接受衍生物，以及它们的制备方法和在人体或动物体内治疗或预防系统性或局部微生物感染中的用途。

  公开号：

  WO2004101587A1

文献信息

• [EN] MACROLIDES SUBSTITUDED AT THE 4"-POSITION<br/>[FR] MACROLIDES SUBSTITUES EN POSITION 4''
  申请人：GLAXO GROUP LTD

  公开号：WO2004101585A1

  公开（公告）日：2004-11-25

  The present invention relates to 14- or 15-membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.

  本发明涉及在式(I)的4'位置被取代的14-或15-元大环内酯及其药学上可接受的衍生物，以及它们的制备过程和在人体或动物体内治疗或预防全身或局部微生物感染中的用途。
• [EN] ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS<br/>[FR] MACROLIDES A LIAISON ESTER UTILES POUR LE TRAITEMENT D'INFECTION MICROBIENNES
  申请人：PLIVA ISTRAZIVACKI INST D O O

  公开号：WO2005108412A1

  公开（公告）日：2005-11-17

  The present invention relates to 14- or 15-membered macrolides substituted at the 4” position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infoections in a human or animal body.

  本发明涉及在式（I）的4”位置被取代的14-或15-环大环内酯及其药学上可接受的衍生物，以及它们的制备方法和在人体或动物体内治疗或预防全身或局部微生物感染中的用途。
• Macrolides With Anti-Inflammatory Activity
  申请人：Culic Ognjen

  公开号：US20080221046A1

  公开（公告）日：2008-09-11

  The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides substituted at the 4″ position, to their pharmaceutically acceptable derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their activity and use in the treatment of inflammatory diseases and conditions in humans and animals, especially those diseases associated with excessive secretion of TNF-α, IL-1, IL-8, IL-2 or IL-5; and/or inhibitor of excessive lymphocyte proliferation; and/or excessive granulocyte degranulation.

  本发明涉及具有抗炎活性的新型半合成大环内酯类化合物。更具体地说，该发明涉及在4″位置取代的14-和15-环大环内酯类化合物，及其药学上可接受的衍生物，用于其制备的工艺和中间体，含有它们的制剂，以及它们在治疗人类和动物的炎症性疾病和症状中的活性和用途，特别是那些与过度分泌TNF-α、IL-1、IL-8、IL-2或IL-5有关的疾病；和/或抑制过度淋巴细胞增殖；和/或过度粒细胞脱颗粒的抑制剂。
• Ester Linked Macrolides Useful For The Treatment of Microbial Infections
  申请人：Alihodzic Sulejman

  公开号：US20080255060A1

  公开（公告）日：2008-10-16

  The present invention relates to 14- or 15-membered macrolides substituted at the 4″ position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.

  本发明涉及在式(I)的4"位置取代的14或15元大环内酯及其药学上可接受的衍生物，以及它们的制备方法和在人或动物体内治疗或预防系统性或局部微生物感染的用途。
• 4″-O-(ω-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens
  作者：A. Fajdetić、H. Čipčić Paljetak、G. Lazarevski、A. Hutinec、S. Alihodžić、M. Đerek、V. Štimac、D. Andreotti、V. Šunjić、J.M. Berge、S. Mutak、M. Dumić、S. Lociuro、D.J. Holmes、N. Maršić、V. Eraković Haber、R. Spaventi

  DOI：10.1016/j.bmc.2010.06.049

  日期：2010.9

  Four macrolides-6-O-methyl-8a-aza-8a-homoerythromycin, clarithromycin, azithromycin and azithromycin 11,12-cyclic carbonate, have been selected for the construction of a series of new quinolone derivatives. The quinolone moiety is connected to the macrolide scaffold via a diaminoaklyl 4"-O-propionyl ester chain of varying length. At the terminus the linker is attached via one of the nitrogen atoms in the linker at C(6) or C(7) of the quinolone. Many of compounds described, particularly clarithromycin derivative 37, and azithromycin derivatives 48 and 55, exhibited excellent antibacterial activity against a wide range of clinically relevant macrolide-resistant organisms, with profiles superior to that of telithromycin, an enhanced spectrum ketolide. (C) 2010 Elsevier Ltd. All rights reserved.